Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GRDX NASDAQ:INCR NASDAQ:NBRV NASDAQ:ZYBT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGRDXEntero Therapeutics$3.64+5.5%$2.38$1.06▼$5.84$11.60M1.38112,434 shs288,996 shsINCRInterCure$0.81-1.0%$0.79$0.68▼$1.77$44.84M1.2446,217 shs6,303 shsNBRVNabriva Therapeutics$0.00$1.22▼$8.45$45.46M1.5329,344 shsN/AZYBTZhengye Biotechnology$0.95-1.0%$0.91$0.68▼$13.08$45.46M-2.4771,571 shs18,372 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGRDXEntero Therapeutics+5.51%+27.72%+76.70%+18.95%+363,999,900.00%INCRInterCure-0.98%-3.45%+8.27%-9.78%-46.58%NBRVNabriva Therapeutics0.00%0.00%0.00%0.00%-98.00%ZYBTZhengye Biotechnology-0.98%-2.83%-15.94%-1.26%-88.75%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGRDXEntero Therapeutics$3.64+5.5%$2.38$1.06▼$5.84$11.60M1.38112,434 shs288,996 shsINCRInterCure$0.81-1.0%$0.79$0.68▼$1.77$44.84M1.2446,217 shs6,303 shsNBRVNabriva Therapeutics$0.00$1.22▼$8.45$45.46M1.5329,344 shsN/AZYBTZhengye Biotechnology$0.95-1.0%$0.91$0.68▼$13.08$45.46M-2.4771,571 shs18,372 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGRDXEntero Therapeutics+5.51%+27.72%+76.70%+18.95%+363,999,900.00%INCRInterCure-0.98%-3.45%+8.27%-9.78%-46.58%NBRVNabriva Therapeutics0.00%0.00%0.00%0.00%-98.00%ZYBTZhengye Biotechnology-0.98%-2.83%-15.94%-1.26%-88.75%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGRDXEntero Therapeutics 0.00N/AN/AN/AINCRInterCure 1.00SellN/AN/ANBRVNabriva Therapeutics 0.00N/AN/AN/AZYBTZhengye Biotechnology 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest GRDX, INCR, NBRV, and ZYBT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/1/2026ZYBTZhengye Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)3/27/2026INCRInterCure Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 5/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGRDXEntero Therapeutics$36.25K337.58N/AN/A$7.42 per share0.49INCRInterCure$78.47M0.57N/AN/A$2.11 per share0.38NBRVNabriva Therapeutics$35.59M0.00N/AN/A$0.10 per share0.00ZYBTZhengye Biotechnology$16.64M2.71N/AN/A$0.93 per share1.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGRDXEntero Therapeutics-$6.39M-$1.69N/AN/AN/AN/A-60.44%-7.05%N/AINCRInterCure-$10.37M$0.0327.07N/AN/AN/AN/AN/AN/ANBRVNabriva Therapeutics-$57.19M-$19.20N/AN/AN/A-148.11%-365.53%-135.81%N/AZYBTZhengye Biotechnology-$9.98MN/AN/AN/AN/AN/AN/AN/AN/ALatest GRDX, INCR, NBRV, and ZYBT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2026Q4 2025GRDXEntero TherapeuticsN/A-$1.88N/A-$1.88N/AN/A4/30/2026Q4 2025INCRInterCureN/A-$0.10N/A-$0.10N/A$23.15 million4/28/2026Q4 2025ZYBTZhengye BiotechnologyN/A-$0.0750N/A-$0.0750N/A$3.97 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGRDXEntero TherapeuticsN/AN/AN/AN/AN/AINCRInterCureN/AN/AN/AN/AN/ANBRVNabriva TherapeuticsN/AN/AN/AN/AN/AZYBTZhengye BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGRDXEntero TherapeuticsN/A0.170.17INCRInterCure0.201.480.97NBRVNabriva Therapeutics0.120.850.52ZYBTZhengye Biotechnology0.031.140.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGRDXEntero Therapeutics12.30%INCRInterCure8.34%NBRVNabriva Therapeutics0.27%ZYBTZhengye BiotechnologyN/AInsider OwnershipCompanyInsider OwnershipGRDXEntero Therapeutics0.75%INCRInterCure0.24%NBRVNabriva Therapeutics1.63%ZYBTZhengye BiotechnologyN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGRDXEntero Therapeutics93.36 million3.34 millionN/AINCRInterCure35054.68 million54.55 millionOptionableNBRVNabriva Therapeutics7032.02 million31.49 millionNot OptionableZYBTZhengye Biotechnology27847.39 millionN/AN/AGRDX, INCR, NBRV, and ZYBT HeadlinesRecent News About These CompaniesZhengye Biotechnology Holding Limited Announces Fiscal Year 2025 Financial ResultsApril 28, 2026 | prnewswire.comZhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share Structure Effective April 7, 2026April 6, 2026 | quiverquant.comQZhengye Biotechnology Holding Limited Announces Implementation of Dual-Class Share StructureApril 6, 2026 | globenewswire.comZhengye Biotechnology Holding Ltd ZYBTMarch 28, 2026 | morningstar.comMZhengye Biotechnology Shareholders Approve Governance and Share Structure Changes at March 24 AGMMarch 25, 2026 | tipranks.comZhengye Biotechnology Director Resigns, Nasdaq Independence Deficiency to Be Addressed at March AGMFebruary 23, 2026 | tipranks.comZhengye Biotechnology Holding Limited Issues 2026 Chairman’s Letter to ShareholdersFebruary 11, 2026 | markets.businessinsider.comZhengye Biotechnology Holding Limited Highlights 2025 Achievements and 2026 Strategic Plan in Shareholder LetterFebruary 10, 2026 | quiverquant.comQZhengye Biotechnology Holding Limited Issues 2026 Chairman's Letter to ShareholdersFebruary 10, 2026 | globenewswire.comWhy Zhengye Biotechnology Holding Limited’s (ZYBT) Stock Is Up 5.27%January 11, 2026 | aaii.comAIs Zhengye Biotechnology Holding Limited's (NASDAQ:ZYBT) ROE Of 3.8% Concerning?September 14, 2025 | finance.yahoo.comZhengye Biotechnology Holding Ltd trading resumesAugust 22, 2025 | msn.comZhengye Biotechnology Holding Ltd trading halted, volatility trading pauseAugust 21, 2025 | msn.comZYBT | Zhengye Biotechnology Holding Ltd. Company Profile & Executives ...July 17, 2025 | wsj.comZhengye Biotechnology Holding Limited Announces Fiscal Year 2024 Financial Results | ZYBT Stock NewsJuly 3, 2025 | gurufocus.comZhengye Biotechnology Holding Limited Announces Fiscal Year 2024 Financial ResultsJuly 3, 2025 | prnewswire.comZYBT | Zhengye Biotechnology Holding Ltd. Stock Overview (U.S.: Nasdaq) - Barron'sJuly 2, 2025 | barrons.comZYBT - Zhengye Biotechnology Holding Ltd Chart - MorningstarJune 27, 2025 | morningstar.comMZhengye Biotechnology Holding LtdJune 21, 2025 | morningstar.comMZYBT Zhengye Biotechnology Holding LimitedMay 30, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines1 Stock Is Powering the AI Boom and the Next Farm SupercycleBy Jeffrey Neal Johnson | April 22, 20263 AI Small-Cap Stocks With Strong Insider and Institutional Buy-InBy Thomas Hughes | April 23, 2026Apple’s Earnings Make $300 Look Like a Matter of When, Not IfBy Sam Quirke | May 1, 2026Meta Posted Its Best Sales Growth Since 2021—So Why Did Shares Fall?By Leo Miller | April 30, 2026Aehr Test Systems: Small AI Stock Sees Record AI Hyperscaler OrderBy Leo Miller | April 22, 2026GRDX, INCR, NBRV, and ZYBT Company DescriptionsEntero Therapeutics NASDAQ:GRDX$3.64 +0.19 (+5.51%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$3.64 0.00 (0.00%) As of 08:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis. It is also involved in the development of adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, currently under Phase 2 studies for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, currently under Phase 2 studies for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, as well as immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is based in Boca Raton, Florida.InterCure NASDAQ:INCR$0.81 -0.01 (-0.98%) Closing price 05/14/2026 03:59 PM EasternExtended Trading$0.81 0.00 (0.00%) As of 05/14/2026 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.Nabriva Therapeutics NASDAQ:NBRVNabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.Zhengye Biotechnology NASDAQ:ZYBT$0.95 -0.01 (-0.98%) Closing price 05/14/2026 04:00 PM EasternExtended Trading$0.94 -0.01 (-1.46%) As of 07:20 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas YETI Rallies After Earnings Beat and Raised Outlook Cisco’s Vertical Rally May Still Be in the Early Innings Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs Dividend Growth or High Yield: The Income Investor's Bet Nebius Upside Expands as AI Feedback Loop Intensifies 2 Ways to Play the Big Pharma Patent Cliff Oklo Stock Could Be Ready for Another Massive Run Amazon vs. Alibaba: One Is Clearly The Better Value Play right Now Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
